Teladoc (TDOC) PT Raised to $110 at RBC Capital

RBC Capital analyst Sean Dodge raised the price target on Teladoc (NYSE: TDOC) to $110.00 (from $100.00) while maintaining an Outperform rating.

The analyst commented, "The InTouch acquisition strengthens our confidence in TDOC's ability to sustain 20-30% organic revenue growth longer, better balances its strategy (provider vs. payer/consumer) and further distances it from peers as the virtual health leader. The 4Q pre-announcement also points to a brighter International outlook. That said, we are moderating our EBITDA estimates to reflect a higher expected level of reinvestment."

You May Also Be Interested In

• AppLovin Corp (APP) PT Lowered to $510 at Evercore ISI, 'Taking a More Cautious Q4/FY27 View'
• UBS Starts Assembly Biosciences (ASMB) at Buy
• Kepler Cheuvreux Upgrades Entain PLC (ENT:LN) (GMVHF) to Buy